FDA permits trial of Omeros drug for thrombotic microangiopathies

04/3/2014 | FDAnews

Omeros obtained the FDA's approval to initiate a midstage trial of its monoclonal antibody candidate OMS721 in patients with complement-mediated thrombotic microangiopathies. The trial, which will test the safety and efficacy of the drug, is scheduled to start this quarter.

View Full Article in:

FDAnews

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA